Corcept Therapeutics (NASDAQ:CORT) Shares Up 10.3% – What’s Next?

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) traded up 10.3% during trading on Wednesday . The company traded as high as $34.50 and last traded at $37.2980. 81,249 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,995,047 shares. The stock had previously closed at $33.82.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval for relacorilant (Lifyorli) + nab‑paclitaxel opens a new commercial indication (platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer). This is the clear immediate catalyst for buying interest — approval arrived ahead of prior timelines and creates a concrete revenue opportunity for Corcept’s lead drug. FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab‑Paclitaxel for Treatment of Patients with Platinum‑Resistant Ovarian Cancer
• Positive Sentiment: Analyst support: H.C. Wainwright reiterated a Buy and set a $60 target, signaling sell‑side backing for upside based on the approval and longer‑term sales potential. Analyst commentary likely reinforced investor demand. Corcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
• Positive Sentiment: Insider buying and renewed focus on relacorilant’s regulatory path have supported momentum — a director’s disclosed open‑market purchase and renewed regulatory catalysts helped convince traders that management/patient insiders see value ahead. That positioning amplified the rally. Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst
• Neutral Sentiment: Trading mechanics: the stock experienced a Regulatory LULD pause (trading halt) during the intraday move — a routine market safeguard during large price swings that can intensify short‑term volatility.
• Neutral Sentiment: Widespread media coverage amplified intraday momentum as outlets reported the approval and the rapid price reaction; high volume and short‑covering likely intensified the move. What’s Behind The Jump In Corcept Therapeutics Stock?
• Negative Sentiment: Litigation risk: multiple law firms have filed/are soliciting plaintiffs in securities class actions tied to past regulatory issues and alleged disclosure problems (lead‑plaintiff deadlines in April). Ongoing litigation can create legal expenses, distraction, and investor uncertainty. Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) – Deadline on April 21, 2026
• Negative Sentiment: Insider selling: a disclosed sale by William Guyer (reported March 20) reduced his holdings materially; such sales can be read negatively by some investors even when not unusual or pre‑planned. Insider trade details for William Guyer

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a report on Wednesday, December 31st. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Finally, HC Wainwright cut their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $77.17.

Corcept Therapeutics Trading Up 21.3%

The business’s fifty day moving average is $37.34 and its 200-day moving average is $61.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The firm has a market cap of $4.36 billion, a P/E ratio of 50.24 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.26 earnings per share. Analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. The trade was a 94.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director G Leonard Baker, Jr. purchased 100,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. The trade was a 9.55% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have sold 60,000 shares of company stock valued at $2,241,035. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Corcept Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Abacus FCF Advisors LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at $3,238,000. JPMorgan Chase & Co. raised its stake in Corcept Therapeutics by 223.4% during the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after buying an additional 587,053 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Corcept Therapeutics by 6,796.7% in the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after buying an additional 384,896 shares during the period. Brown Capital Management LLC bought a new stake in Corcept Therapeutics during the third quarter valued at $19,950,000. Finally, Cerity Partners LLC boosted its position in Corcept Therapeutics by 21.4% during the second quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock valued at $54,800,000 after acquiring an additional 131,799 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.